Voltaren

Product brand

Voltarol is a consumer-health brand of diclofenac-based topical pain-relief medicines, primarily marketed in the United Kingdom and Ireland.

Last updated October 14, 2026

AI crawler reads

No AI crawler has read this profile since Oct 28, 2026.

Overview

Voltaren is a pharmaceutical pain-relief brand built around diclofenac, a non-steroidal anti-inflammatory drug used to reduce pain and inflammation. Depending on the country and formulation, Voltaren products are available by prescription or over the counter and are marketed for conditions including osteoarthritis, joint pain, muscle pain, sports-related injuries, and other localized musculoskeletal complaints. Its best-known formats are topical gels, including diclofenac sodium or diclofenac diethylammonium preparations, although the brand has also been associated in different markets with tablets, creams, patches, liquid-filled capsules, and other delivery systems. The brand developed through the international pharmaceutical businesses that preceded Novartis and later became part of the consumer-health portfolios assembled by GlaxoSmithKline. In 2015, Novartis and GSK announced a major asset exchange that transferred Novartis consumer-health products, including Voltaren in many markets, to GSK. GSK Consumer Healthcare subsequently became part of Haleon, which was separated from GSK and listed as an independent company in 2022. Ownership and commercialization arrangements can vary by market, and some prescription rights or generic versions have been licensed to other pharmaceutical companies. Voltaren's commercial proposition emphasizes targeted relief and maintaining everyday mobility. Topical products are positioned as an alternative or complement to oral pain medicines for appropriate users, particularly people experiencing osteoarthritis or localized joint and muscle pain. Product names, active-ingredient concentrations, indications, legal status, and packaging differ across jurisdictions; consumers are therefore expected to follow local labeling and professional medical advice. The brand's advertising commonly uses movement, sport, family activities, and return-to-routine narratives rather than presenting pain relief solely as a clinical intervention. The United States provides an important example of the brand's regulatory expansion. GSK received FDA approval in 2020 for Voltaren Arthritis Pain, an over-the-counter version of diclofenac sodium topical gel 1% for temporary relief of arthritis pain in certain joints. Before that decision, Voltaren Gel had been marketed in the United States as a prescription product, with Endo Pharmaceuticals holding exclusive U.S. marketing rights under an earlier licensing agreement with Novartis. The U.S. switch broadened consumer access while requiring new labeling, education, retail, and advertising activity. Voltaren remains one of the most recognizable topical pain-relief brands internationally, but its position is shaped by national medicine regulations, generic competition, safety requirements for NSAIDs, and scrutiny of claims and pricing. A significant Australian enforcement action demonstrated the importance of transparent differentiation: regulators and the Federal Court found that Voltaren Osteo Gel and Voltaren Emulgel had essentially the same formulation and efficacy for the relevant use, while marketing and recommended prices had suggested otherwise. The case resulted in penalties against Novartis and GSK and changes to packaging. The episode is part of the brand's documented corporate history, not evidence that every Voltaren product is identical across markets.

History

Voltaren is an international brand for diclofenac-based medicines. Its history is linked to the development and commercialization of diclofenac within the European pharmaceutical industry and to the succession of corporate owners that managed the product in different national markets. The brand has never been a single globally uniform product: concentrations, dosage forms, indications, naming conventions, prescription status, and licensees have differed according to local regulation. For much of its history, Voltaren was associated with prescription treatment for inflammatory and degenerative musculoskeletal conditions. Topical gel became particularly important because it delivered diclofenac to painful areas while supporting a consumer proposition centered on localized relief. In parallel, products using the Voltaren name appeared in other forms, including oral medicines and topical formats. Local subsidiaries and licensees handled manufacturing, registration, promotion, and distribution. Novartis became a major corporate steward of the brand through its pharmaceutical and consumer-health businesses. In 2008, Novartis licensed exclusive U.S. marketing rights for prescription Voltaren Gel to Endo Pharmaceuticals. Endo presented the agreement as a way to expand the product's presence in the U.S. topical NSAID market. The arrangement illustrates how ownership of a trademark and commercialization rights could be separated by territory and product status. A major corporate transition occurred in 2015, when Novartis and GlaxoSmithKline completed a broad asset exchange. GSK acquired Novartis's consumer-health business, including Voltaren among other established self-care brands. GSK Consumer Healthcare then managed Voltaren's consumer marketing in many countries. In 2019, GSK and Pfizer completed the transaction that created the consumer-health joint venture, combining brands such as GSK's Voltaren with Pfizer's Advil and Centrum. That business was later separated from GSK and became Haleon, an independently listed consumer-health company in 2022. The brand's regulatory history includes movement from prescription to non-prescription access. In the United States, Voltaren Gel had initially been prescription-only. In 2020, the FDA approved GSK's Voltaren Arthritis Pain for OTC use, enabling consumers to obtain diclofenac sodium topical gel 1% without a prescription for labeled arthritis-pain uses. The launch required broad consumer education because OTC labeling and self-selection place greater responsibility on users to understand contraindications, dosing limits, interactions, and when medical evaluation is appropriate. Marketing has consistently connected Voltaren with mobility. Campaigns have used movement, work, exercise, family relationships, and the emotional consequences of pain to distinguish the brand from generic clinical descriptions. Examples include the international 'The Joy of Movement' platform, the UK film 'Pain is Drama,' the U.S. 'Forever Paula' campaign featuring Paula Abdul, and earlier print and outdoor executions. These campaigns support a positioning based not merely on suppressing symptoms but on helping people resume meaningful activities. Voltaren has also faced regulatory and reputational scrutiny. In Australia, the ACCC challenged claims and pricing associated with Voltaren Osteo Gel and Voltaren Emulgel. The Federal Court accepted admissions that the products were essentially the same gel and that marketing had made Osteo Gel appear more effective; recommended retail pricing for Osteo Gel was also higher. The court ordered penalties totaling $4.5 million against the relevant Novartis and GSK entities. GSK and Novartis acknowledged the conduct and amended packaging. The case remains an important example of the need for substantiated comparative claims in consumer healthcare. Today Voltaren is an active Haleon brand with broad international recognition. Its commercial scope includes topical pain-relief products and, in selected markets, other diclofenac formats. Its competitive environment includes branded and generic topical NSAIDs, oral analgesics, physical therapies, and other self-care products. Continued growth depends on regulatory compliance, responsible communication, product availability, medical and consumer education, and adaptation to market-specific rules.

2022
Haleon becomes independent owner
[9]Consumer-health portfolio transferred to GSKfinance.yahoo.com
Following the separation of GSK’s consumer-health business, Voltarol became part of Haleon’s standalone consumer-health portfolio.
2020
U.S. prescription-to-OTC switch
[1]FDA approves GSK's Voltaren Arthritis Pain for over-the-counter use in the United Statesus.gsk.com
The FDA approved GSK's Voltaren Arthritis Pain for over-the-counter use in the United States.
2020
Australian consumer-law penalties
[2]GSK and Novartis to pay $4.5 million in penalties over Voltaren Osteo Gel claimsaccc.gov.au
The Federal Court ordered $4.5 million in penalties over misleading comparative marketing and pricing of Voltaren Osteo Gel and Emulgel.
2019
Generic U.S. reference-product approval
[4]Perrigo generic Voltaren Gel approval announcementperrigo.com
Perrigo announced FDA final approval for an AB-rated generic version of Voltaren Gel 1%.
2015
Consumer-health portfolio transferred to GSK
[9]Consumer-health portfolio transferred to GSKfinance.yahoo.com
The Novartis-GSK asset exchange transferred Voltaren and other consumer-health brands to GSK's consumer-health business in many markets.
2008
U.S. marketing-rights licensing agreement
[3]Endo Pharmaceuticals Voltaren Gel licensing announcementsec.gov
Endo Pharmaceuticals announced exclusive U.S. marketing rights for prescription Voltaren Gel under a five-year agreement with Novartis.
Diclofenac becomes the active-ingredient foundation
Diclofenac, the NSAID used in Voltarol products, was developed and introduced by Ciba-Geigy before becoming a widely marketed medicine through regional brands.
Voltarol established as a regional diclofenac brand
The Voltarol name became associated primarily with topical diclofenac medicines in the United Kingdom and Ireland, while Voltaren was used in many other countries.

Products and positioning

Accessible, science-based pain and inflammation relief focused on restoring movement and managing localized musculoskeletal pain. A pharmacy and consumer-health brand focused on localized relief of pain and inflammation through topical diclofenac medicines.

Topical OTC analgesic · 2020
Voltaren Arthritis Pain Gel
A diclofenac sodium topical gel marketed in the United States for temporary relief of arthritis pain in certain joints. It received OTC approval in 2020 after previously being available in the United States as a prescription product. Directions, age restrictions, warnings, and eligible sites of application are governed by U.S. labeling.
Topical diclofenac medicine
Voltaren Emulgel
A topical diclofenac product sold in multiple markets under the Emulgel name. It is used for localized pain and inflammation associated with musculoskeletal conditions, subject to local indications and legal status. The formulation and packaging may not be identical in every country.
Topical arthritis-pain medicine
Voltaren Osteo Gel
A Voltaren-branded topical gel associated particularly with osteoarthritis pain in Australia and other markets. Australian regulators found that it was essentially the same gel as Emulgel for the relevant use, leading to enforcement action over comparative claims and pricing.
Prescription topical NSAID
Prescription Voltaren Gel
Diclofenac sodium topical gel 1% marketed as a prescription medicine in the United States before the later OTC switch. Novartis licensed exclusive U.S. marketing rights to Endo Pharmaceuticals in 2008.
Topical NSAID gel
Voltarol Emulgel
Voltarol Emulgel is the brand’s best-known type of product: a diclofenac-containing gel applied to the skin over a painful or inflamed area. It is marketed for localized musculoskeletal complaints such as sprains, strains, and certain joint or muscle pains. The precise diclofenac concentration, authorized indications, pack sizes, directions, and legal status depend on the country and product variant.
Topical pain-relief medicine
Voltarol topical gel
The Voltarol name is used for market-specific topical diclofenac gel products beyond the Emulgel designation. These products are intended for direct application to affected areas and are positioned as non-systemic or locally delivered alternatives within the broader pain-relief category. Availability and formulation details vary by market and may change as regulatory authorizations and portfolio policies evolve.

Controversies

2020
Misleading Osteo Gel and Emulgel comparisons in Australia
The Australian Federal Court found that Novartis and GSK marketing made Voltaren Osteo Gel appear more effective than Voltaren Emulgel even though the products were essentially the same gel for the relevant osteoarthritis use. The court also noted that Osteo Gel's recommended retail price could be up to 16% higher. Penalties totaled $4.5 million, and packaging was subsequently amended.
Source
2020
Federal Court fines GSK and Novartis over Osteo Gel marketing
The Federal Court ordered GlaxoSmithKline to pay $1.5 million and Novartis to pay $3 million after the companies admitted breaching Australian consumer law through their marketing of Osteo Gel between 2012 and 2017. The court found that the marketing misled consumers about the product's effectiveness compared with Emulgel.
Source 1 Source 2

2020The Joy of Movement
Global
A Publicis-led global platform developed the idea that movement enables human connection and contributes to genuine joy. Its launch was linked to findings from GSK Consumer Healthcare's Global Pain Index.
Source
2020Forever Paula
United States
A Weber Shandwick campaign featuring Paula Abdul presented Voltaren Arthritis Pain Gel as part of her dance routine and preparation for performing.
Source
2019Pain is Drama
United Kingdom
A Saatchi & Saatchi film campaign dramatized how pain can dominate ordinary situations and positioned Voltaren as a way to regain control and movement.
Source
2012TAPIS
France
A Voltaren Pain Relief Gel advertising execution created by Buzzman Paris and identified in advertising archives as a 2012 French campaign.
Source
2011Crane, Forklift, Bulldozer
Switzerland
A Saatchi & Saatchi print campaign used images associated with heavy machinery to communicate the burden of pain and the value of movement.
Source
Move Freely with Voltaren
Unspecified
A brand-awareness campaign emphasized pain relief, reduced inflammation, and the ability to participate more freely in daily activities. The available reference does not establish a reliable year or market.
Source

Brand decisions

2022
Transfer the brand to HaleonM&A
Background
GSK separated its consumer-health business into an independent company.
Action taken
Voltaren became part of Haleon's standalone portfolio.
Aftermath
Haleon continued the brand's consumer-health commercialization across its markets.
Source
2022
Consumer-health portfolio separated into HaleonStrategy
Background
Voltarol had been managed within GSK’s consumer-health operations, but GSK separated those operations into a new standalone consumer-health company.
Action taken
The Voltarol brand was transferred to Haleon as part of the separation and public listing of the consumer-health business.
Aftermath
Voltarol continued as a Haleon consumer-health brand, while GSK retained its prescription-medicine and vaccines businesses.
2020
Move Voltaren Arthritis Pain from prescription to OTC in the United StatesStrategy
Background
GSK sought to broaden access to topical diclofenac for adults with eligible osteoarthritis pain.
Action taken
The FDA approved Voltaren Arthritis Pain for over-the-counter use.
Aftermath
GSK prepared a large multichannel launch involving retail, digital, television, print, radio, and consumer education.
Source
2015
Transfer Voltaren into GSK Consumer HealthcareM&A
Background
Novartis and GSK reorganized their pharmaceutical and consumer-health assets through a large strategic transaction.
Action taken
GSK acquired Novartis's consumer-health business, including Voltaren in relevant markets.
Aftermath
GSK became the principal consumer-health steward of the brand until the later formation of Haleon.
Source
2008
License U.S. prescription marketing rights to EndoOther
Background
Novartis sought to expand the U.S. presence of topical diclofenac in the emerging topical NSAID market.
Action taken
Novartis granted Endo Pharmaceuticals exclusive U.S. marketing rights for prescription Voltaren Gel under a five-year agreement.
Aftermath
Endo planned an initial specialty-sales launch followed by broader physician promotion.
Source

Recent events

2022
Haleon continues Voltaren consumer-health operations after separation from GSK[9]Consumer-health portfolio transferred to GSKfinance.yahoo.com
M&A · Other
Voltaren became part of Haleon's independent consumer-health portfolio when Haleon was separated from GSK and listed as a standalone company.
2022
Haleon becomes the owner of the Voltarol brand following its separation from GSK
M&A
Voltarol entered Haleon’s standalone consumer-health portfolio when GSK separated and listed Haleon. The brand had previously been part of GSK Consumer Healthcare.
2020
FDA approves Voltaren Arthritis Pain for over-the-counter use in the United States[1]FDA approves GSK's Voltaren Arthritis Pain for over-the-counter use in the United Statesus.gsk.com
Product launch · Regulation
GSK announced FDA approval for an OTC version of Voltaren Arthritis Pain, expanding access to diclofenac topical treatment for eligible consumers.
2019
Perrigo receives FDA approval for an AB-rated generic Voltaren Gel[4]Perrigo generic Voltaren Gel approval announcementperrigo.com
Product launch · Regulation
Perrigo announced final FDA approval for a generic diclofenac sodium topical gel 1% referencing Voltaren Gel.
2008
Endo obtains exclusive U.S. marketing rights for Voltaren Gel[3]Endo Pharmaceuticals Voltaren Gel licensing announcementsec.gov
M&A · Other
Endo Pharmaceuticals announced a five-year licensing agreement with Novartis for exclusive U.S. marketing rights to prescription Voltaren Gel.

Sources16 sources

Cite this profile: Cite the canonical profile. /brand-wiki/voltaren · Editorial policy · How profiles are compiled